Proposed adoption of the h share incentive scheme and proposed general mandate to repurchase h shares
Filed with HKEX · Stock code 2335 · · 4 pages · English
Summary by 6ix AI
Shaanxi Micot Pharmaceutical Technology Co., Ltd. is proposing the adoption of an H Share Incentive Scheme and a general mandate to repurchase H Shares, as detailed in the filing. The H Share Incentive Scheme aims to attract and reward eligible participants while aligning their interests with those of the company and its shareholders. The company believes its H Shares are undervalued and seeks approval from shareholders to repurchase a portion of them. An extraordinary general meeting will be convened to discuss these proposals and a circular with further details will be sent to shareholders.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Shaanxi Micot Pharmaceutical Technology Co., Ltd. on 6ix
Earlier from Shaanxi Micot Pharmaceutical Technology
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Notification letter to non-registered shareholders and reply form
- 2026 Interim report
- Announcement of allotment results
- List of directors and their roles and functions
Later from Shaanxi Micot Pharmaceutical Technology
- Proposed general mandate to repurchase h shares and notice of extraordinary general meeting
- Notice of extraordinary general meeting
- Proxy form for the extraordinary general meeting to be held on 10 November 2026
Follow Shaanxi Micot Pharmaceutical Technology into a list and get an email when it puts out news.
Follow Shaanxi Micot Pharmaceutical Technology